



**DATE CLINICAL BACKGROUND & STUDY DETAILS**

3.24.26

**History:** Historically has elevated liver enzyme levels. Grade 3/6 heart murmur. Has been hyporexic for almost a year. Getting her to eat is a real challenge for the O.

**PATIENT**

Sadie Miller

**-CXR:** cardiomegaly.

**Pertinent abnormal PE/Chem/CBC/UA Results:** ALP>2000, ALT 158, lipase 2121

**Current medications:** Vetmedin 5mg 1/2 BID- 3mo, Lasix 12.5mg 1/2 SID- BID- 3mo, Ursodiol 250mg 1/4 SID years, Mirtazepine 15mg 1/2 SID 1 mo, i/d diet

**Sedation used:** Torbugesic.

**SPECIES**

Canine

**Pertinent previous ultrasound results:** No previous.

**STAT:** Not requested.

**Imaging performed by:** Stephanie Warga RDCS, RVT.

**BREED**

Pug

**RADIOGRAPHIC FINDINGS** \*NOTE: Images submitted for supplemental information only.

Mild cardiomegaly. No obvious evidence of CHF.

**SEX**

FS

**ECHOCARDIOGRAM FINDINGS**

2D, m-mode, color flow and doppler imaging is available. Diffuse thickening of mitral valve leaflets (anterior>posterior) with mild prolapse into the left atrial lumen. Moderate eccentric mitral regurgitation with moderate left atrial dilation. Normal MR velocity. Mildly increased LV diameter with hyperdynamic myocardial function. The tricuspid valve appears mildly thickened, with trace tricuspid regurgitation. Normal velocity. Normal right atrial and ventricular diameter. The pulmonic and aortic valves are normal in morphology and mobility. Normal pulmonic and aortic outflow velocities. No aortic or pulmonic insufficiency. No pericardial or pleural effusion noted. No cardiac tumors observed.

9.13.12

**WEIGHT**

32.2lbs

**CARDIAC CHART**

**INTERPRETED BY**

Maggie Machen Lamy,  
DVM, DACVIM  
(Cardiology)

<b>CANINE CARDIAC PARAMETERS</b>	<b>MR VMAX</b> (m/s)	<b>TR VMAX</b> (m/s)	<b>LA/AO</b> (Boon method)	<b>LA/AO</b> (Heart Base; Swe)	<b>FS</b> (%)	<b>EF</b> (%)	<b>EPSS</b> (cm)
<b>NORMAL PARAMETER</b>	4.5-5.5	<2.7	1.3	<1.6	28-40	40-100	<0.6
<b>PATIENT</b>	5.5	3.0	NM	1.7	52	84	NM
<b>CANINE CARDIAC PARAMETERS</b>	<b>HR</b> (BPM)	<b>AV VMAX</b> (m/s)	<b>PV MAX</b> (m/s)	<b>BODY WEIGHT</b> (kg)	<b>LA</b> 2D short axis Base view (cm)	<b>LVIDd</b> Avg; 2D and m-mode short axis (cm)	<b>LVIDs</b> Avg; 2D and m-mode short axis (cm)
<b>NORMAL PARAMETER</b>	50-100	0.7-1.7	0.7-1.6	BELOW	BELOW	BELOW	BELOW
<b>PATIENT</b>	85	2.0	1.1	14.6	2.7	4.2	2.0
*Normal chamber parameters expressed as a mean value (SD)				3	1.27 (5.3)	2.46 (2.46)	1.36 (5.5)
<b>BODY WEIGHT DEPENDENT PARAMETERS</b>				5	1.40 (4.5)	2.74 (5.2)	1.60 (4.7)
*Note: All measurements based upon multi-modal images and methods. An average value is reported.				10	1.50 (3.8)	3.27 (3.5)	2.06 (3.1)
				15	1.83 (2.0)	3.71 (2.4)	2.43 (2.1)
				20	2.02 (1.9)	4.14 (2.2)	2.80 (2.0)
				25	2.18 (2.4)	4.48 (2.9)	3.10 (2.5)
				30	2.33 (3.3)	4.83 (3.9)	3.39 (3.4)
Adapted from June Boon, Veterinary Echocardiography, 1998							

**HOSPITAL NAME**

Greenbrier VC

**REFERRING VET**

Dr. Dellinger

**INVOICE**

47286

Rishniw M and Hollis NE, J Vet Intern Med 2000; 14:429-435	35	2.48 (4.3)	5.17 (5.0)	3.69 (4.5)
Hansson et al, Vet Rad and Ultrasound 2002	40	2.62 (5.2)	5.48 (6.1)	3.96 (5.4)
Bonagura et al. Echocardiography: principles of interpretation, Vet	50	2.88 (7.1)	6.07 (8.3)	4.46 (7.4)

### **INTERPRETATION OF THE FINDINGS & FURTHER RECOMMENDATIONS**

Chronic degenerative valve disease causing moderate mitral and trace tricuspid regurgitation. Moderate left atrial enlargement indicates there is relatively low risk for imminent complication; however, risk for progression to spontaneous congestive heart failure in the future is elevated. No additional issues such as pulmonary hypertension are identified.

Given these findings, continued Pimobendan is indicated in this patient as below. Unless there is a history of clinical or radiographic CHF, Lasix is likely unnecessary. Assessment of progression in the future will help predict long term outcome; however, prognosis is guarded at this stage (B2). Fifty percent of stage B2 patients typically develop CHF within 2-2.5 years of diagnosis. The median time to development of CHF in B2 cases treated with pimobendan is 3.5 years.

Omega fatty acid supplementation and mild salt restriction may also be of some long-term benefit. Monitor for development of a progressive cough, labored breathing, exercise intolerance or collapse episodes.


Anesthetic risk is considered mildly elevated. Cardiac protective drug choices (opioid/benzodiazepine premedication, Propofol or alfaxalone induction, iso or sevo gas) are recommended. Monitor for arrhythmias, hypotension, and hypoxia both intra and post-operatively and intervene as necessary. Judicious IV fluid rates are recommended to avoid fluid overload. Avoid heart rate stimulating drugs such as atropine unless clinically indicated.

### **PLAN**

Baseline BP recommended. Continue Pimobendan 0.25-0.3mg/kg PO q12h. Unless CHF has been documented, Lasix can be discontinued.

Recommend monitor for progression with a recheck echocardiogram in 6 months, sooner if any development of clinical signs.

### **IMAGES**



**The information and recommendations provided are based on the images presented by the referring veterinarian. No evaluation can be communicated regarding pathology that was not visible in the image/video clips provided.**

Thank you for this referral. This report was generated using transcription software, and minor dictation errors may be present. If the clinical or image interpretation does not parallel your findings or if I can be of any further assistance, please contact me.

**Maggie Machen Lamy, DVM**  
**Diplomate of the American College of Veterinary Internal Medicine (Cardiology)**  
**info@sonopath.com**